Press Release Details

G1 Therapeutics to Participate in Two Upcoming Conferences

November 10, 2021 at 11:40 AM EST

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences.

  • On November 17, 2021 at 8:00 AM EST, G1’s Chief Executive Officer Jack Bailey will present at the Stifel 2021 Virtual Healthcare Conference.

  • On December 1, 2021 at 12:35 PM EST, Mr. Bailey will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference.

The webcast of both events will be accessible on the Events & Presentations page of

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating trilaciclib in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit and follow us on Twitter @G1Therapeutics.

Will Roberts
Vice President, Investor Relations & Corporate Communications

Primary Logo

Source: G1 Therapeutics